Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGATO: Effect of ocrelizumab on leptomeningeal inflammation in progressive multiple sclerosis
2021-003296-33Phase 4Completed
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Started Dec 2021; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-003296-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003296-33.